Skip to main content

Table 3 Relationship between BCL2L12 statusa and other clinicopathological variables.

From: BCL2L12 is a Novel Biomarker for the Prediction of Short-Term Relapse in Nasopharyngeal Carcinoma

  

Number of patients (%)

 
 

Total

BCL2L12-negative

BCL2L12-positive

P

Cases

79

37 (46.8)

42 (53.2)

 

Sex

    

Male

51

19 (37.3)

32 (62.7)

0.033b

Female

28

18 (64.3)

10 (35.7)

 

Age (years)

    

≤30

25

11 (44.0)

14 (56.0)

0.81b

>30

54

26 (48.1)

28 (51.9)

 

Tumor histologyc

    

Undifferentiated

40

23 (57.5)

17 (42.5)

0.045b

Nonkeratinizing

38

13 (34.2)

25 (65.8)

 

Unknown

1

   

Tumor extentd

    

T1/T2

28

17 (60.7)

11 (39.3)

0.099b

T3/T4

51

20 (39.2)

31 (60.8)

 

Regional lymph node status

    

N0

7

6 (85.7)

1 (14.3)

0.17e

N1

12

6 (50.0)

6 (50.0)

 

N2

28

12 (42.9)

16 (57.1)

 

N3

32

13 (40.6)

19 (59.4)

 

Distant metastasis

    

M0

55

31 (56.4)

24 (43.6)

0.014b

M1

24

6 (25.0)

18 (75.0)

 
  1. aCutoff point: 1.95 c/c, equal to the 47th percentile.
  2. bCalculated by χ2 test.
  3. cHistology classification system, established by the World Health Organization.
  4. dStaging system, established by the American Joint Committee on Cancer (21,22).
  5. eCalculated by Fisher exact test.